Spadrot MF contains drotaverine and mefenamic acid.
It is an anti-spasmodic drug which is structurally related to papaverine. It has no anticholinergic effect and is a selective phosphodiesterase 4 inhibitor. Drotaverine is shown to possess a dose dependent analgesic effect.
It is a NSAID which is used for the treatment of pain. It decreases the swelling in inflammation and also uterine contractions. It also inhibits PG synthesis.
- Muscle pain
- Migraine headache
- Functional bowel disorders
- Heavy bleeding during periods
- Abdominal pain
- Pain after surgery
- Pain in renal colic
- Pain during periods
- It also blocks the substances which causes inflammation
Adult: 40-80 mg tid.
Child: 1-6 yr: 20 mg 3-4 times daily; >6 yr: 40 mg tid.
It is an anti-spasmodic drug which produces its effect by inhibition of phosphodiasterase-4 which is specific for smooth muscle. It produces its fast duration of action on smooth muscle. It maintains the cAMP and Ca balance at spastic site, thereby relieving smooth muscle spasm and pain.
It produces its pharmacological action by binding to prostaglandin synthetase receptors COX-1 and COX-2 and causes the inhibition of its action. As these plays a major role in causing inflammation.
After administration it is well absorbed in the body. It is a spasmolytic agent by inhibiting phosphodiesterase enzyme 4 in smooth muscle cells. Bioavailability of the drug is highly variable. It get rapidly absorbed from duodenal ileal segments
The protein binding of the drug is about 80-95%. The drug follows hepatic metabolism. The half life of the drug is 7 to 12hrs.
The excretion of the drug is through biliary excretion and feces.
It is rapidly absorbed after oral administration. The mean peak levels of mefenamic acid are ranging from 10-20mcg/ml3. Co-administration of mefenamic with antacid increases the absorption rate of magnesium hydroxide.
It is well distributed in the body with 90% of the drug is bound to plasma protein. The volume of distribution of the drug is 1.06 l/kg. It is metabolized by liver cytochrome P450 enzyme CYP2C9 to 3-hydroxymethyl mefenamic acid (Metabolite I).
About 52% of the drug is excreted in urine as glucuronides of mefenamic acid. About 20% of the drug is excreted through urine.
- Patients hypersensitive to its ingredients
- Its use in pregnancy, especially in first and third trimester
- In severe cases of hepatic, renal, cardiac dysfunction
- Mefenamic acid should not be administered to the patients with asthma, urticaria or allergic reactions
- Pre-operative pain in coronary artery bypass graft (CABG) surgery
- Cautiously used in patients with hepatic, renal and cardiac dysfunction
- Patients with pregnancy and lactation
- Cannot be substituted for corticosteroid therapy